Condition
KRAS G12D Mutations clinical trials and research
As of November 12, 2026, Find a Trial lists 2 KRAS G12D Mutations clinical trials that are recruiting, in China. By phase: Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
RNK08954 treatment for metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation
This study tests whether RNK08954 is safe and helps people with metastatic pancreatic ductal adenocarcinoma who have a KRAS G12D mutation.
-
Testing GFH375 in patients with advanced solid tumors that have KRAS G12D mutations
This study is testing a new drug called GFH375 to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation.
Related topics
Quick answers
How many KRAS G12D Mutations clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.